| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1995;91:1427-1431.)
© 1995 American Heart Association, Inc.
Articles |
Shear-Induced Platelet Aggregation Is Inhibited by In Vivo Infusion of an Anti–Glycoprotein IIb/IIIa Antibody Fragment, c7E3 Fab, in Patients Undergoing Coronary Angioplasty
From the Cox Laboratory for Biomedical Engineering (K.K., J.D.H.), Rice University, Houston, Tex; the Department of Medicine (S.G.K., A.I.S., N.S.K.) and Department of Pathology (E.I.B.), Baylor College of Medicine, Houston, Tex; and Centocor, Inc (R.J.), Malvern, Pa.
Correspondence to J. David Hellums, PhD, Cox Laboratory for Biomedical Engineering, Rice University, Houston, TX 77251-1892.
Background Elevated levels of shear stress such as those that occur in stenotic arterial vessels can directly activate and aggregate platelets and thus contribute to the pathogenesis of acute arterial thrombosis. This shear-induced platelet aggregation (SIPA) is mediated by von Willebrand factor binding to platelet membrane glycoprotein (GP) Ib and GPIIb/IIIa. The chimeric Fab fragment of the monoclonal antibody 7E3 (c7E3 Fab) that binds selectively to GPIIb/IIIa is under clinical evaluation in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). This study was undertaken to investigate the effects on ex vivo SIPA of c7E3 Fab administered to patients undergoing PTCA.
Methods and Results Six patients received aspirin (325 mg) and boluses of heparin (12 000 U) followed by c7E3 Fab 0.25 mg/kg. Blood collected from each patient before and after heparin treatment and at various time points after c7E3 Fab administration was subjected to laminar shear stress in a cone-and-plate viscometer. Flow cytometry was used to quantify the extents of platelet aggregation and of antibody binding to GPIIb/IIIa. Results indicate that c7E3 Fab injection resulted in a rapid, extensive blockade of GPIIb/IIIa receptors (98.6±0.2%) and a 50% inhibition of ex vivo platelet aggregation induced by shear stress. c7E3 Fab also completely abolished the formation of large platelet aggregates ("large" refers to particles >10 µm in equivalent sphere diameter), which are presumably the aggregates of greatest clinical significance. Partial reversibility of the inhibition was noted within 2 days after drug administration, but even after 1 week, platelet function had not been fully restored.
Conclusions This study demonstrates that c7E3 Fab is a potent inhibitor of SIPA, which may be an important mechanism of its beneficial effect in the treatment of arterial occlusive diseases and in the prevention of thrombotic complications of coronary artery disease after angioplasty.
Key Words: platelets • glycoproteins • platelet aggregation inhibitors • angioplasty
This article has been cited by other articles:
 |
|
 |
|
  B. Salanova, M. Choi, S. Rolle, M. Wellner, F. C. Luft, and R. Kettritz beta2-Integrins and Acquired Glycoprotein IIb/IIIa (GPIIb/IIIa) Receptors Cooperate in NF-{kappa}B Activation of Human Neutrophils J. Biol. Chem., September 21, 2007; 282(38): 27960 - 27969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Goto, N. Tamura, and H. Ishida Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions J. Am. Coll. Cardiol., July 21, 2004; 44(2): 316 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Osende, V. Fuster, E. I. Lev, D. Shimbo, U. Rauch, J. D. Marmur, M. Richard, D. Varon, and J. J. Badimon Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests : Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition Circulation, March 20, 2001; 103(11): 1488 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Abulencia, N. Tien, O. J. T. McCarty, D. Plymire, S. A. Mousa, and K. Konstantopoulos Comparative Antiplatelet Efficacy of a Novel, Nonpeptide GPIIb/IIIa Antagonist (XV454) and Abciximab (c7E3) in Flow Models of Thrombosis Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 149 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Kettner, O. P. Panzer, S. A. Kozek, F. A. Seibt, B. Stoiser, J. Kofler, G. J. Locker, and M. Zimpfer Use of abciximab-Modified Thrombelastography in Patients Undergoing Cardiac Surgery Anesth. Analg., September 1, 1999; 89(3): 580 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goto, H. Sakai, M. Goto, M. Ono, Y. Ikeda, S. Handa, and Z. M. Ruggeri Enhanced Shear-Induced Platelet Aggregation in Acute Myocardial Infarction Circulation, February 9, 1999; 99(5): 608 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Tam, P. M. Sassoli, R. E. Jordan, and M. T. Nakada Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and {alpha}vß3 Integrins Circulation, September 15, 1998; 98(11): 1085 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Geiser, M. Sturzenegger, U. Genewein, A. Haeberli, and J. H. Beer Mechanisms of Cerebrovascular Events as Assessed by Procoagulant Activity, Cerebral Microemboli, and Platelet Microparticles in Patients With Prosthetic Heart Valves Stroke, September 1, 1998; 29(9): 1770 - 1777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dangas, J. J. Badimon, B. S. Coller, J. T. Fallon, S. K. Sharma, R. M. Hayes, P. Meraj, J. A. Ambrose, and J. D. Marmur Administration of Abciximab During Percutaneous Coronary Intervention Reduces Both Ex Vivo Platelet Thrombus Formation and Fibrin Deposition : Implications for a Potential Anticoagulant Effect of Abciximab Arterioscler Thromb Vasc Biol, August 1, 1998; 18(8): 1342 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Chesebro and J. J. Badimon Platelet Glycoprotein IIb/IIIa Receptor Blockade in Unstable Coronary Disease N. Engl. J. Med., May 21, 1998; 338(21): 1538 - 1541. [Full Text]
|
|
|
|
|
|
M. A. Mascelli, E. T. Lance, L. Damaraju, C. L. Wagner, H. F. Weisman, and R. E. Jordan Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade Circulation, May 5, 1998; 97(17): 1680 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon, C. H. McCabe, S. Borzak, T. D. Henry, M. D. Tischler, H. S. Mueller, R. Feldman, S. T. Palmeri, K. Ault, S. A. Hamilton, et al. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome : Results of the TIMI 12 Trial Circulation, February 3, 1998; 97(4): 340 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Mascelli, S. Worley, N. J. Veriabo, E. T. Lance, S. Mack, T. Schaible, H. F. Weisman, and R. E. Jordan Rapid Assessment of Platelet Function With a Modified Whole-Blood Aggregometer in Percutaneous Transluminal Coronary Angioplasty Patients Receiving Anti-GP IIb/IIIa Therapy Circulation, December 2, 1997; 96(11): 3860 - 3866. [Abstract] [Full Text]
|
|
|
|
|
|
T. R. Investigators Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty Circulation, September 2, 1997; 96(5): 1445 - 1453. [Abstract] [Full Text]
|
|
|
|
|
|
R. R. Makkar, F. Litvack, N. L. Eigler, M. Nakamura, P. A. Ivey, J. S. Forrester, P. K. Shah, R. E. Jordan, and S. Kaul Effects of GP IIb/IIIa Receptor Monoclonal Antibody (7E3), Heparin, and Aspirin in an Ex Vivo Canine Arteriovenous Shunt Model of Stent Thrombosis Circulation, February 18, 1997; 95(4): 1015 - 1021. [Abstract] [Full Text]
|
|
|
|
|
|
R. K. Aggarwal, D. C. Ireland, M. A. Azrin, M. D. Ezekowitz, D. P. de Bono, and A. H. Gershlick Antithrombotic Potential of Polymer-Coated Stents Eluting Platelet Glycoprotein IIb/IIIa Receptor Antibody Circulation, December 15, 1996; 94(12): 3311 - 3317. [Abstract] [Full Text]
|
|